Abstract
Purpose
To retrospectively evaluate the toxicity of concurrent weekly cisplatin and radiation therapy (RT) for locally advanced cervical cancer.
Materials and Methods
Between April 2001 and December 2004, 21 consecutive previously untreated patients with locally advanced cervical cancer were treated with concurrent chemoradiation therapy (CCRT) at the Tokushima University Hospital. Clinical stages were II: 5, III: 15, IVA: 1. External beam radiation therapy (EBRT) was delivered with 10 MV X-rays, 2 Gy fraction per day; total dose to the whole pelvis was 50 Gy. Iridium-192 high-doserate (HDR) intracavitary radiation therapy was performed with 10–30 Gy (median, 24 Gy) targeted at point A. Concurrent chemotherapy consisted of cisplatin, administered weekly at a dose of 40 mg/m2 for patients who were younger than 65 years and 30 mg/m2 for those 65 years or over. A maximum single dose of cisplatin, up to 70 mg/body, was administered in 5 cycles during EBRT.
Results
A total of 86 cycles of cisplatin were administered to the 21 patients, with a median of 4 cycles (range, 2–5). Severe hematological toxicity occurred in 18 patients (86%), including grade 3 in 17 patients (81%) and grade 4 in one patient (4.8%). Moderate or severe gastrointestinal toxicity occurred in 11 patients (52%), including grade 2 in 10 patients (48%) and grade 3 in one patient (4.8%). The grades of hematological toxicity were significantly greater in the 40 mg/m2 group than in the 30 mg/m2 group. All of the patients who were administered 40 mg/m2 of cisplatin developed grade 3 or greater hematological toxicity, including one patient with grade 4 toxicity. In the 30 mg/m2 group, 3 of 10 patients developed less than grade 3 toxicity, and all patients completed radiation therapy without interruption.
Conclusion
The incidence of severe acute hematological toxicity was significantly higher in this study than in previously reported randomized controlled trials (RCTs), especially in the group of 40 mg/m2 cisplatin. A dose of 30 mg/m2 of cisplatin was considered to be feasible in weekly cisplatin and radiation therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Morris M, Eifel PJ, Lu J,et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer.N Engl J Med, 340: 1137–1143, 1999.
Rose PG, Bundy BN, Watkins EB,et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.N Engl J Med, 340: 1144–1153, 1999.
Keys HM, Bundy BN, Stehman FB,et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.N Engl J Med, 340: 1154–1161, 1999.
Whitney CW, Sause W, Bundy BN,et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.J Clin Oncol, 17: 1339–1348, 1999.
Peters WA 3rd, Liu PY, Barrett RJ 2nd,et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk ealy-stage cancer of the cervix.J Clin Oncol, 18: 1606–1613, 2000.
Shepherd JH. Staging announcement: FIGO staging of gynecologic cancers. Cervical and vulva.Int J Gynecol Cancer, 5: 319, 1995.
Tod MC, Meredith WJ A dosage system for use in the treatment of cancer of uterine cervix.Brit J Radiol, 11: 809–817, 1938.
National Cancer Institute (NCI). Common toxicity criteria. Bethesda, Maryland: Division of Cancer Treatment, National Cancer Institute, 1988.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).Int J Radiat Oncol Biol Phys, 31: 1341–1346, 1995.
Green JA, Kirwan JM, Tierney JF,et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis.Lancet, 358: 781–786, 2001.
Kirwan JM, Symonds P, Green JA,et al. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer.Radiother Oncol 68:217–226, 2003.
Souhami L, Seymour R, Roman TN,et al. Weekly cisplatin plus external beam radiotherapy and high dose rate brachytherapy in patients with locally advanced carcinoma of the cervix.Int J Radiat Oncol Biol Phys, 27:871–878, 1993.
Abu-Rustum NR, Lee, S, Correa A,et al. Compliance with and acute hematologic toxic effects of chemoradiation in indigent women with cervical cancer.Gynecol Oncol, 81: 88–91, 2001.
Strauss HG, Kuhnt T, Laban C,et al. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of phase-II study.Strahlenther Onkol, 178: 378–385, 2002.
Serkies K, Jassem J. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity.Int J Radiat Oncol Biol Phys, 60: 814–821, 2004.
Ohara K, Tanaka Oishi Y, Tsunoda H,et al. Preliminary estimation of treatment effect on uterine cervical squamous cell carcinoma in terms of tumor regression rate: comparison between chemoradiotherapy and radiotherapy alone.Radiation Medicine, 23: 25–29, 2005.
Author information
Authors and Affiliations
About this article
Cite this article
Ikushima, H., Osaki, K., Furutani, S. et al. Chemoradiation therapy for cervical cancer: Toxicity of concurrent weekly cisplatin. Radiation Medicine 24, 115–121 (2006). https://doi.org/10.1007/BF02493277
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02493277